Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Crawford, E. David

doi:10.2147/tcrm.s6863

Cited by 21 publications

(1 citation statement)

References 115 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biodegradable microparticle drug delivery systems can be fabricated to encapsulate various drugs, and tuning them for controlled release 21–23 . Controlled drug release is superior because customizable drug exposure in terms of concentration, localization and duration maximize drug efficacy and mitigate unwanted fluctuations in drug dosage 24,25 . By exploiting engineered particulate drug delivery systems for islets transplanted into the ACE, we have the ability to circumvent current clinical challenges of long-term immunosuppression and low islet functional efficacy.…”

Section: Introductionmentioning

confidence: 99%

Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye

Fan

Zheng

Ali

et al. 2019

Sci Rep

View full text Add to dashboard Cite

The anterior chamber of the eye (ACE) has emerged as a promising clinical islet transplantation site because of its multiple advantages over the conventional intra-hepatic portal site. This includes reduced surgical invasiveness and increased islet graft survival rate. It also allows for enhanced accessibility and monitoring of the islets. Although the ACE is initially an immuno-privileged site, this privilege is disrupted once the islet grafts are re-vascularized. Given that the ACE is a confined space, achieving graft immune tolerance through local immunosuppressive drug delivery is therefore feasible. Here, we show that islet rejection in the ACE of mice can be significantly suppressed through local delivery of rapamycin by carefully designed sustained-release microparticles. In this 30-day study, allogeneic islet grafts with blank microparticles were completely rejected 18 days post-transplantation into mice. Importantly, allogeneic islet grafts co-injected with rapamycin releasing microparticles into a different eye of the same recipient were preserved much longer, with some grafts surviving for more than 30 days. Hence, islet allograft survival was enhanced by a localized and prolonged delivery of an immunosuppressive drug. We envisage that this procedure will relieve diabetic transplant recipients from harsh systemic immune suppression, while achieving improved glycemic control and reduced insulin dependence.

show abstract

Section: Introductionmentioning

confidence: 99%

Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye

Fan

Zheng

Ali

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

Martins

Sousa

Araújo

et al. 2017

Adv Healthcare Materials

205

133

View full text Add to dashboard Cite

Poly(lactic‐co‐glycolic) acid (PLGA) is one of the most versatile biomedical polymers, already approved by regulatory authorities to be used in human research and clinics. Due to its valuable characteristics, PLGA can be tailored to acquire desirable features for control bioactive payload or scaffold matrix. Moreover, its chemical modification with other polymers or bioconjugation with molecules may render PLGA with functional properties that make it the Holy Grail among the synthetic polymers to be applied in the biomedical field. In this review, the physical–chemical properties of PLGA, its synthesis, degradation, and conjugation with other polymers or molecules are revised in detail, as well as its applications in drug delivery and regeneration fields. A particular focus is given to successful examples of products already on the market or at the late stages of trials, reinforcing the potential of this polymer in the biomedical field.

show abstract

Leuprolide Acetate, a GnRH Agonist, Improves Experimental Autoimmune Encephalomyelitis: A Possible Therapy for Multiple Sclerosis

et al. 2012

View full text Add to dashboard Cite

Gonadotrophin-releasing hormone (GnRH), a well known hypothalamic neuropeptide, has been reported to possess neurotrophic properties. Leuprolide acetate, a synthetic analogue of GnRH is considered to be a very safe and tolerable drug and it has been used for diverse clinical applications, including the treatment of prostate cancer, endometriosis, uterine fibroids, central precocious puberty and in vitro fertilization techniques. The present study was designed to determine whether Leuprolide acetate administration, exerts neurotrophic effects on clinical signs, body weight gain, neurofilaments (NFs) and myelin basic protein (MBP) expression, axonal morphometry and cell infiltration in spinal cord of experimental autoimmune encephalomyelitis (EAE) rats. In this work, we have found that Leuprolide acetate treatment decreases the severity of clinical signs of locomotion, induces a significantly greater body weight gain, increases the MBP and NFs expression, axonal area and cell infiltration in EAE animals. These results suggest the use of this agonist as a potential therapeutic approach for multiple sclerosis.

show abstract

Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Cited by 21 publications

References 115 publications

Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye

Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

Leuprolide Acetate, a GnRH Agonist, Improves Experimental Autoimmune Encephalomyelitis: A Possible Therapy for Multiple Sclerosis

Contact Info

Product

Resources

About